Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines

Biochemical Pharmacology

Volumn 51, Issue 10, 1996, Pages 1349-1355

  Drake, James C ^a   Allegra, Carmen J ^a   Moran, Richard G ^b   Johnston, Patrick G ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL NAVAL MEDICAL CENTER   (United States)

Author keywords

breast cancer; colon cancer; folylpolyglutamate synthetase; resistance; thymidylate synthase; Tomudex

Indexed keywords

FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; MESSENGER RNA; METHOTREXATE; PROTEIN; QUINAZOLINE DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0029930070     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00057-3     Document Type: Article

References (27)

1. Danenberg PV, Thymidylate synthase: A target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73-92, 1977.
2. Heidelberger C, Fluorinated pyrimidines and their nucleosides. In: Handbook of Experimental Pharmacology (Eds. Sartorelli AC and Johns DG), Vol. 38, pp. 193-231. Springer, New York, 1975.
3. Cantwell BMJ, MaCauley V, Harris AL, Kaye SB, Smith IE, Milsted RAV and Calvert AH, Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. Eur J Clin Oncol 24: 733-736, 1988.
4. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51: 5579-5586, 1991.
5. Sorensen JM, Jordan E, Grem JL, Hamilton JM, Arbuck SG, Johnston P and Allegra CJ, Phase I trial of D1694. A pure thymidylate synthase inhibitor. Proc Am Soc Clin Oncol 12: 158, 1993.
6. Jodrell DI, Newell DR, Calvert JA, Stephens TC and Calvert AH, Pharmacokinetics and toxicity studies with the novel quinazoline thymidylate synthase inhibitor D1694. Proc Am Assoc Cancer Res 31: 341, 1990.
7. Zalcberg J, Cunningham D, Green M, Francois E, van Cutsem E, Schornagel J, Adenis A, Seymour L and Azab M, The results of a large phase II study of the potent thymidylate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. Proc Am Soc Clin Oncol 14: 204, 1995.
8. Johnston PG, Drake JC, Trepel J and Allegra CJ, Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
9. Soule HD, Vasquez J, Long A, Albert S and Brennan M, A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
10. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
11. Moran RG, Spears CP and Heidelberger C, Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthase. Proc Natl Acad Sci USA 76: 1456-1460, 1979.
12. Roberts D, An isotopic assay for thymidylate synthetase. Biochemistry 5: 3546-3548, 1966.
13. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
14. Antonsson B, Barredo J and Moran RG, A microassay for mammalian folylpolyglutamate synthetase. Anal Biochem 186: 8-13, 1990.
15. Chomczynski P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
16. Davis RW, Rapid DNA isolations for enzymatic and hybridization analysis. Methods Enzymol 31: 404-411, 1980.
17. Modi WS, Nash W, Ferreri A and O'Brien S, Cytogenetic methodologies for gene mapping and comparative analysis in mammalian cell culture systems. Gene Anal Tech 4: 75-85, 1987.
18. 10-propargyl-5,8-dideazafolic acid (CB3717): Development, characterization, and cross-resistance studies. Cancer Res 46: 2810-2815, 1986.
19. 10-propargyl-5,8-dideazafolic acid: A novel folate-based thymidylate synthase inhibitor. Cancer Res 52: 1137-1143, 1992.
20. Freemantle SJ, Jackman AL, Kelland LR, Calvert AH and Lunec J, Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer 71: 925-930, 1995.
21. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT, Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924, 1995.
22. Lu K, Yin M-B, McGuire JJ, Bonmassar E and Rustum YM, Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem. Pharmacol 50: 391-398, 1995.
23. Jansen G, Schornagel JH, Westerhof GR, Rijksen G, Newell DR and Jackman AL, Multiple membrane transport systems for the uptake of folate based thymidylate synthase inhibitors. Cancer Res 50: 7544-7548, 1990.
24. Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL and Schornagel JH, Membrane transport of natural folates and antiofolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor-mediated transport systems. Cancer Res 51: 5507-5513, 1991.
25. McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G and Mini E, Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266: 6181-6187, 1991.
26. Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG and Beardsley GP, Multifactorial resistance to 5,10-dideazatretrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 55: 566-573, 1995.
27. Wang F-S, Aschele C, Sobrero A, Chang Y-M and Bertino JR, Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance. Cancer Res 53: 3677-3680, 1993.